When Disruption Becomes the Default in the Clinical Trial Supply Chain: Q&A with Hal Green, Loftware
By: Andy Studna, Hal Green
In this Q&A, Hal Green, senior solution architect and life sciences vertical lead EMEA at Loftware, examines how clinical supply chain fragmentation has shifted from an efficiency problem into a resilience problem—and what it takes to build infrastructure capable of absorbing disruption without losing trial continuity.





